Sydney, Australia — 28 November 2022 — Inventia Life Science, a global leader in 3D cell culture and 3D bioprinting technology will build a new advanced manufacturing hub in Sydney thanks to support from the NSW Government's Jobs Plus Program.
The support will go towards infrastructure to dramatically increase Inventia’s current manufacturing capacity to support its international commercial expansion. The Company is currently transitioning from an initial soft-launch phase of RASTRUM™3D bioprinter, and biomaterials to a full commercial scale-up. Inventia has seen a strong international and domestic demand from top 10 pharmaceutical companies and research institutes for RASTRUM™. Currently, four of the top 10 pharmaceutical companies globally use RASTRUM™ for drug development and meeting this demand will initiate flow-on growth across Inventia’s technical and commercial teams.
This new facility will enable Inventia’s manufacturing footprint to increase from roughly 430 square meters to 1500 square meters. Within the new facility will be state-of-the-art laboratory facilities and it will be the headquarters for all of Inventia’s Australian employees, which will stand at a total of 110 people by the end of this year.
The grant will also enable Inventia to create 76 direct new jobs in NSW by FY24, to support the new advanced manufacturing facility, R&D lab space and associated commercialisation activities. Jobs will be created across all of Inventia’s practices including Life Science, Manufacturing and Production, Go-to-Market, Finance and Operations, Software Engineering and Customer Success and Support.
Finally, Inventia intends to use the funds to expand its support of training programs for new Inventia employees to upskill on knowledge in deep technical engineering and product management courses.
Inventia’s Founder and CEO, Dr Julio Ribeiro said:
“We are delighted by the support we have been given by the NSW Government. As a result of the Jobs Plus grant we have been able to scale-up our production capabilities, employ more highly skilled people including biologists, software and mechanical engineers and take this revolutionary technology to the world.
Inventia's drop-on-demand 3D bioprinting technology is the most advanced and precise 3D printing of its kind in the world. It is well placed to consolidate Australia as a global leader in this field. These additional funds will help us cement Australia's position and expand our global presence.”
Media Enquiries
Elle Kress
media@inventia.life
+61 490 472 947
.webp)